Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Major Depressive Disorder
Merck Sharp & Dohme LLCSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 65/ 100
Competitive context
235 Active assets in the Major Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zelapar Corium Innovations, Inc. | Phase 4 | BBB |
Risperdal Johns Hopkins University | Phase 4 | BBB |
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
S-Ketamine Janssen Research & Development, LLC | Phase 4 | BBB |
Vortioxetine Mayo Clinic | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →